PPARG and metabolic dysfunction-associated steatohepatitis: Insulin resistance is a hallmark of NASH, hence insulin sensitizers, such as PPARγ agonist thiazolidinediones (TZDs) and metformin, have shown efficacy in rodent models of NASH-HCC [183,184].